NEVVI Medicare utilization intelligence

← back

ZIMMERMAN, DAVIDM.D. NPI 1639148232 Clinician

Hematology-Oncology · FORT WAYNE, IN

Specialty Hematology-Oncology — from billed Medicare claims
Trained INDIANA UNIVERSITY SCHOOL OF MEDICINE — medical school, self-reported to CMS
In practice about 29 years since medical school (class of 1997, self-reported to CMS)
Location FORT WAYNE, IN · NPPES registered location
Active in data Billed Medicare 2020–2024 (5 consecutive years)
Scale 39 codes billed · 54,259 disclosed services (CY2024 — most recent year in data)
Current groups

Group affiliation since 2019

20192026
AMERICAN ONCOLOGY PARTNERS PA
2025–2026
FORT WAYNE MEDICAL ONCOLOGY AND HEMATOLOGY INC
2019–2024

The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.

NPPES registry · CMS Doctors & Clinicians registry · Medicare Part B physician/supplier claims · NPPES record last updated 2025-05

Year: 2024 · 2023 · 2022  · 2021  · 2020 

Provider overview · all codes · CY2024

The full analytics for this provider

Premium

The billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.

This provider's disclosed Medicare payments across all codes were in CY2024. Unlock to see the figure.

  • Payment, service & beneficiary totals — the disclosed scale, all codes
  • Practice profile — focus & reach — top codes by share of services
  • Office vs. facility setting mix — place-of-service code split
  • Volume over five years — discrete yearly counts, no rate
  • Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
  • Peer positioning — code breadth — how many codes billed, vs peers

Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.

Notify me at launch → Or see a live example profile →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)
J9271 Injection, pembrolizumab, 1 mg
J1453 Injection, fosaprepitant, 1 mg
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
J0897 Injection, denosumab, 1 mg
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J2469 Injection, palonosetron hcl, 25 mcg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
96375 Injection of additional new drug or substance into vein
96413 Administration of chemotherapy into vein, 1 hour or less
J2405 Injection, ondansetron hydrochloride, per 1 mg
J3480 Injection, potassium chloride, per 2 meq
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
J9045 Injection, carboplatin, 50 mg
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
96372 Injection of drug or substance under skin or into muscle
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
96415 Administration of chemotherapy into vein, each additional hour
J1200 Injection, diphenhydramine hcl, up to 50 mg
96361 Infusion into a vein for hydration, each additional hour
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
96417 Administration of additional new drug or substance into vein, 1 hour or less
J7030 Infusion, normal saline solution , 1000 cc
J3490 Unclassified drugs
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
A9552 Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries
78815 Nuclear medicine study from skull base to mid-thigh with ct scan
96360 Infusion into a vein for hydration, 31-60 minutes
71260 Ct scan of chest with contrast
74177 Ct scan of abdomen and pelvis with contrast
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit)
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
38222 Biopsy and aspiration of bone marrow sample for diagnosis
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.